Trials / Terminated
TerminatedNCT00269828
A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.
Paclitaxel Poliglumex (CT-2103) vs. Paclitaxel for the Treatment of Women With Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) Who Are Performance Status 2.
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 600 (planned)
- Sponsor
- CTI BioPharma · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, open-label, multinational, phase III study in women with histologically- or cytologically-confirmed advanced NSCLC who are chemotherapy naïve and have PS 2. Study drug will be administered on day 1 of each 21 day cycle
Detailed description
See Summary
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | paclitaxel | |
| DRUG | paclitaxel poliglumex |
Timeline
- Start date
- 2005-12-01
- Completion
- 2006-12-01
- First posted
- 2005-12-26
- Last updated
- 2020-11-24
Locations
143 sites across 11 countries: United States, Argentina, Bulgaria, Canada, Hungary, Mexico, Poland, Romania, Russia, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT00269828. Inclusion in this directory is not an endorsement.